Study: NCT03558152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A Placebo
Description: The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A Placebo
Description: The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A Placebo
Description: The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UTTR1147A Placebo
Description: The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UTTR1147A Placebo
Description: The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Vedolizumab will be administered IV, as specified in the prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Placebo
Description: The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Placebo
Description: The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Placebo
Description: The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Placebo
Description: The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Placebo
Description: The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Placebo
Description: The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab Placebo
Description: The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.